We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Inovio (INO) This Earnings Season?
Read MoreHide Full Article
Inovio Pharmaceuticals, Inc. (INO - Free Report) is scheduled to report first-quarter 2018 results on May 9.
Shares of Inovio have outperformed the industry in a year’s time. The stock has gained 8.3% against the industry’s decrease of 13.1%.
Inovio’s earnings performance has been a mixed bag over the last four quarters. The company surpassed expectations on three occasions while lagging the same once. Overall, it delivered an average miss of 4.68%.
Last quarter, the company surpassed the Zacks Consensus Estimate with a positive surprise of 25%. Let’s see how things are shaping up for this announcement.
Factors to Consider
Given that Inovio’s portfolio is devoid of any revenue-generating product, investors’ focus will remain on its pipeline as well as regulatory updates on the conference call.
VGX-3100 is the most advanced candidate in the company’s pipeline. Inovio is conducting a pivotal phase III REVEAL program to evaluate the safety and efficacy of VGX-3100 for the treatment of cervical dysplasia caused by human papillomavirus (“HPV”). Another phase II study is examining the efficacy of VGX-3100 in women with HPV-related vulvar neoplasia.
Apart from VGX-3100, Inovio has several candidates in its pipeline in early-to-mid-stage development. Also, the company is working to develop Ebola, Zika and Middle East respiratory syndrome virus vaccines.
In the quarter, Inovio amended its license and collaboration agreement with ApolloBio Corporation related to development and commercialization VGX-3100 for HPV within Greater China. The amended agreement includes an increase in upfront payment and excludes equity provisions.
In January 2018, the company announced that its universal influenza vaccine demonstrated protective antibody responses against all major strains of H1N1 influenza viruses from the last 100 years.
Inovio received milestone payment from Medimmune related to advancing of MEDI0457 and checkpoint inhibitor combination trial in head and neck squamous cell cancer to phase II in January.
The company’s top line varies on a quarterly basis, depending on the timing of receipt of collaboration revenues.
Earnings Whispers
Our proven model does not conclusively show that Inovio is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Zacks ESP: Inovio has an Earnings ESP of 0.00% because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 27 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Inovio carries a Zacks Rank #3, which increases the predictive power of ESP. However, a company’s 0.00% ESP makes surprise prediction difficult.
We caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Array BioPharma Inc. (ARRY - Free Report) has an Earnings ESP of +21.19% and a Zacks Rank #2. The company is scheduled to release first-quarter results on May 9.
Adverum Biotechnologies, Inc. (ADVM - Free Report) has an Earnings ESP of +6.9% and currently carries a Zacks Rank #3. The company is expected to release first-quarter results on May 8.
Inovio Pharmaceuticals, Inc. Price and EPS Surprise
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
What's in the Cards for Inovio (INO) This Earnings Season?
Inovio Pharmaceuticals, Inc. (INO - Free Report) is scheduled to report first-quarter 2018 results on May 9.
Shares of Inovio have outperformed the industry in a year’s time. The stock has gained 8.3% against the industry’s decrease of 13.1%.
Inovio’s earnings performance has been a mixed bag over the last four quarters. The company surpassed expectations on three occasions while lagging the same once. Overall, it delivered an average miss of 4.68%.
Last quarter, the company surpassed the Zacks Consensus Estimate with a positive surprise of 25%. Let’s see how things are shaping up for this announcement.
Factors to Consider
Given that Inovio’s portfolio is devoid of any revenue-generating product, investors’ focus will remain on its pipeline as well as regulatory updates on the conference call.
VGX-3100 is the most advanced candidate in the company’s pipeline. Inovio is conducting a pivotal phase III REVEAL program to evaluate the safety and efficacy of VGX-3100 for the treatment of cervical dysplasia caused by human papillomavirus (“HPV”). Another phase II study is examining the efficacy of VGX-3100 in women with HPV-related vulvar neoplasia.
Apart from VGX-3100, Inovio has several candidates in its pipeline in early-to-mid-stage development. Also, the company is working to develop Ebola, Zika and Middle East respiratory syndrome virus vaccines.
In the quarter, Inovio amended its license and collaboration agreement with ApolloBio Corporation related to development and commercialization VGX-3100 for HPV within Greater China. The amended agreement includes an increase in upfront payment and excludes equity provisions.
In January 2018, the company announced that its universal influenza vaccine demonstrated protective antibody responses against all major strains of H1N1 influenza viruses from the last 100 years.
Inovio received milestone payment from Medimmune related to advancing of MEDI0457 and checkpoint inhibitor combination trial in head and neck squamous cell cancer to phase II in January.
The company’s top line varies on a quarterly basis, depending on the timing of receipt of collaboration revenues.
Earnings Whispers
Our proven model does not conclusively show that Inovio is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Zacks ESP: Inovio has an Earnings ESP of 0.00% because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 27 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Inovio carries a Zacks Rank #3, which increases the predictive power of ESP. However, a company’s 0.00% ESP makes surprise prediction difficult.
We caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Aptevo Therapeutics Inc. (APVO - Free Report) has an Earnings ESP of +36.94% and a Zacks Rank #3. The company is expected to release first-quarter results on May 11. You can see the complete list of today’s Zacks #1 Rank stocks here.
Array BioPharma Inc. (ARRY - Free Report) has an Earnings ESP of +21.19% and a Zacks Rank #2. The company is scheduled to release first-quarter results on May 9.
Adverum Biotechnologies, Inc. (ADVM - Free Report) has an Earnings ESP of +6.9% and currently carries a Zacks Rank #3. The company is expected to release first-quarter results on May 8.
Inovio Pharmaceuticals, Inc. Price and EPS Surprise
Inovio Pharmaceuticals, Inc. Price and EPS Surprise | Inovio Pharmaceuticals, Inc. Quote
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>